4. AstraZeneca PLC (NASDAQ:AZN)
AstraZeneca PLC (NASDAQ: AZN) takes fourth place because it has developed one of the pharmaceutical industry’s broadest and most productive growth portfolios. The company is best known for oncology, but it also possesses important businesses in cardiovascular, renal, metabolic, respiratory, immunology and rare-disease medicines. Rather than depending on one dominant drug, AstraZeneca PLC (NASDAQ: AZN) has created multiple commercial franchises capable of supporting long-term revenue growth. That diversification is particularly valuable in an industry where patent expirations can rapidly weaken a company that relies too heavily on a single product.
First-quarter 2026 revenue increased 8% to $15.3 billion, while core earnings per share advanced 5% to $2.58. Management maintained its expectation for full-year revenue growth in the mid-to-high single-digit range. The company entered 2026 with 16 blockbuster medicines after announcing positive results from 16 Phase 3 trials during 2025. That volume of late-stage clinical success matters. A pharmaceutical pipeline can look impressive when it contains dozens of early-stage molecules, but Phase 3 programs have progressed much closer to potential regulatory approval and commercialization. AstraZeneca PLC (NASDAQ: AZN) therefore offers investors a combination of existing product strength and a steady flow of future catalysts.
The company continued building its oncology and rare-disease position during 2026. It received U.S. approval for a fixed-duration combination involving Calquence and venetoclax in chronic lymphocytic leukemia and gained approval for Baxfendy in hypertension. AstraZeneca PLC (NASDAQ: AZN) also licensed a novel oral EGFR inhibitor from Dizal Pharmaceutical, strengthening an already significant lung-cancer franchise. The risks include clinical setbacks, regulatory delays and the high cost of maintaining such an expansive pipeline. Still, the company has repeatedly demonstrated that it can convert scientific programs into commercial medicines. AstraZeneca PLC (NASDAQ: AZN) ranks fourth among the best pharmaceutical stocks because of its balanced growth, oncology leadership, international scale and unusually deep collection of late-stage drug candidates.
Click next to see the following stock...
